BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 36046787)

  • 21. GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone.
    O'Neill KE; Senapati S; Maina I; Gracia C; Dokras A
    J Assist Reprod Genet; 2016 Sep; 33(9):1175-84. PubMed ID: 27349252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J; De Vits A; Joostens M; Van Royen E
    Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GnRH agonist ovulation trigger and hCG-based, progesterone-free luteal support: a proof of concept study.
    Kol S; Humaidan P; Itskovitz-Eldor J
    Hum Reprod; 2011 Oct; 26(10):2874-7. PubMed ID: 21784738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retrospective comparison of GnRH agonist trigger with HCG trigger in GnRH antagonist cycles in anticipated high-responders.
    Datta AK; Eapen A; Birch H; Kurinchi-Selvan A; Lockwood G
    Reprod Biomed Online; 2014 Nov; 29(5):552-8. PubMed ID: 25246126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GnRH agonist trigger with intensive luteal phase support vs. human chorionic gonadotropin trigger in high responders: an observational study reporting pregnancy outcomes and incidence of ovarian hyperstimulation syndrome.
    Christopoulos G; Vlismas A; Carby A; Lavery S; Trew G
    Hum Fertil (Camb); 2016 Sep; 19(3):199-206. PubMed ID: 27662416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective randomized comparison of human chorionic gonadotropin versus intramuscular progesterone for luteal-phase support in assisted reproduction.
    Araujo E; Bernardini L; Frederick JL; Asch RH; Balmaceda JP
    J Assist Reprod Genet; 1994 Feb; 11(2):74-8. PubMed ID: 7819706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prevention of ovarian hyperstimulation syndrome.
    Corbett S; Shmorgun D; Claman P; ;
    J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determinants of the hCG Concentration in the Early Luteal Phase After Final Maturation of Follicles With Bolus Trigger of Recombinant hCG.
    Vuong LN; Pham TD; Ho VNA; Ho TM; Humaidan P; Andersen CY
    Front Endocrinol (Lausanne); 2020; 11():137. PubMed ID: 32265836
    [No Abstract]   [Full Text] [Related]  

  • 29. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles.
    Humaidan P; Van Vaerenbergh I; Bourgain C; Alsbjerg B; Blockeel C; Schuit F; Van Lommel L; Devroey P; Fatemi H
    Hum Reprod; 2012 Nov; 27(11):3259-72. PubMed ID: 22930004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Triggering final follicular maturation--hCG, GnRH-agonist or both, when and to whom?
    Orvieto R
    J Ovarian Res; 2015 Aug; 8():60. PubMed ID: 26293447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ovulation induction and luteal support with GnRH agonist in patients at high risk for hyperstimulation syndrome.
    Fusi FM; Arnoldi M; Bosisio C; Lombardo G; Ferrario M; Zanga L; Galimberti A; Capitanio E
    Gynecol Endocrinol; 2015; 31(9):693-7. PubMed ID: 26527503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gonadotropin-releasing hormone agonist for ovulation trigger - OHSS prevention and use of modified luteal phase support for fresh embryo transfer.
    Castillo JC; Haahr T; Martínez-Moya M; Humaidan P
    Ups J Med Sci; 2020 May; 125(2):131-137. PubMed ID: 32366146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The exogenous progesterone-free luteal phase: two pilot randomized controlled trials in IVF patients.
    Humaidan P; Alsbjerg B; Elbaek HO; Povlsen BB; Laursen RJ; Jensen MB; Mikkelsen AT; Thomsen LH; Kol S; Haahr T
    Reprod Biomed Online; 2021 Jun; 42(6):1108-1118. PubMed ID: 33931371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intranasal gonadotropin-releasing hormone agonist (GnRHa) for luteal-phase support following GnRHa triggering, a novel approach to avoid ovarian hyperstimulation syndrome in high responders.
    Bar-Hava I; Mizrachi Y; Karfunkel-Doron D; Omer Y; Sheena L; Carmon N; Ben-David G
    Fertil Steril; 2016 Aug; 106(2):330-3. PubMed ID: 27114332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.
    Anaya Y; Mata DA; Letourneau J; Cakmak H; Cedars MI; Rosen MP
    J Assist Reprod Genet; 2018 Feb; 35(2):297-307. PubMed ID: 29086322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of GnRH agonist alone or combined with different low-dose hCG on cumulative live birth rate for high responders in GnRH antagonist cycles: a retrospective study.
    He Y; Tang Y; Chen S; Liu J; Liu H
    BMC Pregnancy Childbirth; 2022 Mar; 22(1):172. PubMed ID: 35236312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Day two post retrieval 1500 IUI hCG bolus, progesterone-free luteal support post GnRH agonist trigger - a proof of concept study.
    Vanetik S; Segal L; Breizman T; Kol S
    Gynecol Endocrinol; 2018 Feb; 34(2):132-135. PubMed ID: 28933569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
    Humaidan P; Ejdrup Bredkjaer H; Westergaard LG; Yding Andersen C
    Fertil Steril; 2010 Feb; 93(3):847-54. PubMed ID: 19200959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response to ovulation trigger is correlated to late follicular phase progesterone levels: A hypothesis explaining reduced reproductive outcomes caused by increased late follicular progesterone rise.
    Friis Wang N; Skouby SO; Humaidan P; Andersen CY
    Hum Reprod; 2019 May; 34(5):942-948. PubMed ID: 30927415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.